PBAC's latest decision on Romiplostim: Recommended with restriction (2010). Considered for treatment of thrombocytopaenia in adult patients with chronic immune (idiopathic) thrombocytopaenic purpura (ITP).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 2 submissions
Submissions
2
first 2009
Submissions
2
2009 → 2010
Eligible population
adult patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP)
Therapy area
Haematology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
QoL | other
Key trials
212, 105, 131
Comparator
placebo
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2009–2010) — not a single base case.